Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
In a phase I study, rhenium obisbemeda (186RNL)—an investigational drug developed at the University of Texas Health Science Center at San Antonio—more than doubled median survival and progression-free time, compared with standard median survival and progression rates.
The Wistar Institute’s Paul M. Lieberman and his lab identified and tested a method for targeting certain cancers caused by Epstein-Barr Virus.
Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.
Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.
UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.
In findings published in Clinical Cancer Research, a research team at Mayo Clinic identified specific proteins—fibronectin and smooth muscle actin—within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
The Center for Drug Evaluation of China’s National Medical Products Administration granted Breakthrough Therapy designation to olverembatinib, combination with low-intensity chemotherapy, for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
